Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRNA - Moderna, Inc.

IEX Last Trade
40.27
0.010   0.025%

Share volume: 76,848
Last Updated: Fri 27 Dec 2024 08:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$40.26
0.01
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 6%
Dept financing 8%
Liquidity 56%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.12%
1 Month
-6.82%
3 Months
-38.51%
6 Months
-66.64%
1 Year
-59.86%
2 Year
-77.56%
Key data
Stock price
$40.27
P/E Ratio 
-5.07
DAY RANGE
$39.80 - $41.46
EPS 
-$15.56
52 WEEK RANGE
$38.22 - $170.35
52 WEEK CHANGE
-$59.35
MARKET CAP 
29.752 B
YIELD 
N/A
SHARES OUTSTANDING 
384.396 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,955,742
AVERAGE 30 VOLUME 
$7,787,988
Company detail
CEO: Stéphane Bancel
Region: US
Website: modernatx.com
Employees: 3,900
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Moderna, Inc. develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company has 44 development programs, which includes 26 in clinical trials across seven modalities.

Recent news